📊 NRXPW Key Takeaways
Is NRX Pharmaceuticals, Inc. (NRXPW) a Good Investment?
NRX Pharmaceuticals is in severe financial distress with negative stockholders' equity of -$15.9M, indicating liabilities exceed assets. The company is burning cash at an alarming rate (-$14.1M operating cash flow) with minimal revenue ($1.2M) and massive operating losses (-$16.2M), leaving minimal runway with only $7.8M in cash.
NRX Pharmaceuticals exhibits minimal revenue with extremely negative operating and net margins, reflecting an early-stage profile without commercial scale. With negative shareholders’ equity, a 0.31x current ratio, and $7.8M cash against -$14.1M operating cash flow, liquidity and going-concern risks are acute absent immediate non-dilutive funding or drastic cost reductions.
Why Buy NRX Pharmaceuticals, Inc. Stock? NRXPW Key Strengths
- Maintains $7.8M in cash reserves providing short-term liquidity
- Reduced net loss per share by 69.7% YoY through dilution management
- Minimal capital expenditure ($0) suggesting focus on preservation
- Asset-light model with zero capex requirements
- Some existing revenue base ($1.23M)
- EPS loss improved materially YoY
NRXPW Stock Risks: NRX Pharmaceuticals, Inc. Investment Risks
- Negative stockholders' equity of -$15.9M indicates technical insolvency and potential covenant violations
- Operating cash burn of -$14.1M with only $7.8M cash implies approximately 6.6 months of runway at current burn rate
- Revenue collapsed 15.2% YoY to $1.2M while losses increased, indicating fundamental business deterioration
- Current ratio of 0.31x shows inability to cover short-term obligations
- Liabilities exceed assets by $15.9M with $9.2M long-term debt requiring refinancing
- Operating losses represent 1,324% of revenue, indicating no viable path to profitability
- Severe liquidity shortfall (current ratio 0.31x)
- Negative equity indicating solvency/going-concern risk
- High cash burn and likely need for dilutive financing/recapitalization
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Quarterly revenue trends and pipeline progress
- Covenant compliance on $9.2M long-term debt
- Operating cash flow trajectory
- Stockholders' equity recovery or further deterioration
- Operating cash flow (burn rate)
- Cash & equivalents (runway)
NRX Pharmaceuticals, Inc. (NRXPW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NRXPW Profit Margin, ROE & Profitability Analysis
NRXPW vs Healthcare Sector: How NRX Pharmaceuticals, Inc. Compares
How NRX Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NRX Pharmaceuticals, Inc. Stock Overvalued? NRXPW Valuation Analysis 2026
Based on fundamental analysis, NRX Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NRX Pharmaceuticals, Inc. Balance Sheet: NRXPW Debt, Cash & Liquidity
NRXPW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: NRX Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.98 indicates the company is currently unprofitable.
NRXPW Revenue Growth, EPS Growth & YoY Performance
NRXPW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$1.6M | N/A |
| Q2 2024 | N/A | -$5.5M | N/A |
| Q1 2024 | N/A | -$5.5M | $-0.74 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NRX Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
NRXPW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for NRX Pharmaceuticals, Inc. (CIK: 0001719406)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NRXPW
What is the AI rating for NRXPW?
NRX Pharmaceuticals, Inc. (NRXPW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NRXPW's key strengths?
Claude: Maintains $7.8M in cash reserves providing short-term liquidity. Reduced net loss per share by 69.7% YoY through dilution management. ChatGPT: Asset-light model with zero capex requirements. Some existing revenue base ($1.23M).
What are the risks of investing in NRXPW?
Claude: Negative stockholders' equity of -$15.9M indicates technical insolvency and potential covenant violations. Operating cash burn of -$14.1M with only $7.8M cash implies approximately 6.6 months of runway at current burn rate. ChatGPT: Severe liquidity shortfall (current ratio 0.31x). Negative equity indicating solvency/going-concern risk.
What is NRXPW's revenue and growth?
NRX Pharmaceuticals, Inc. reported revenue of $1.2M.
Does NRXPW pay dividends?
NRX Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find NRXPW SEC filings?
Official SEC filings for NRX Pharmaceuticals, Inc. (CIK: 0001719406) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NRXPW's EPS?
NRX Pharmaceuticals, Inc. has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NRXPW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NRX Pharmaceuticals, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NRXPW stock overvalued or undervalued?
Valuation metrics for NRXPW: ROE of N/A (sector avg: 15%), net margin of -2,336.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NRXPW stock in 2026?
Our dual AI analysis gives NRX Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NRXPW's free cash flow?
NRX Pharmaceuticals, Inc.'s operating cash flow is $-14.1M, with capital expenditures of $0.0. FCF margin is -1,152.0%.
How does NRXPW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,336.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.31 (avg: 2).